MCCC1

MCCC1 encodes the biotin-containing alpha subunit of the mitochondrial 3-methylcrotonyl-CoA carboxylase (MCC) holoenzyme, which catalyzes a biotin-dependent carboxylation step essential for leucine catabolism. The protein harbors a mitochondrial targeting signal, a biotin carboxylase domain, and a biotin-carrier protein domain, and is highly expressed in mitochondria-rich tissues such as heart, skeletal muscle, kidney, and liver (PMID:11406611, PMID:11401427). Loss-of-function mutations in MCCC1 abolish MCC enzyme activity and cause 3-methylcrotonyl-CoA carboxylase deficiency, a Mendelian organic aciduria, with the crystal structure of the holoenzyme providing a molecular framework for understanding pathogenic variants (PMID:14680978, PMID:22869039). Beyond its metabolic role, MCCC1 physically interacts with the pro-apoptotic protein Bad to stabilize it and regulate mitochondrial apoptotic signaling, and serves as a direct binding target of regulatory lncRNAs (lncBADR, AABR07005593.1) that modulate BCAA degradation and NF-κB-driven inflammation (PMID:37805164, PMID:41013574, PMID:34619471).

1. 2001 High

   Cloning of MCCC1 established the molecular identity of the biotin-containing alpha subunit of MCC and linked mutations directly to loss of enzyme activity, resolving the genetic basis of MCC deficiency.

   Evidence cDNA cloning, chromosomal mapping, and enzyme activity assays in patient fibroblasts carrying compound heterozygous mutations

   PMID:11401427 PMID:11406611

   Open questions at the time

   • Three-dimensional structure of the holoenzyme not yet determined
   • Spectrum of pathogenic alleles and genotype-phenotype correlations incomplete
   • No reconstitution of purified recombinant holoenzyme to measure kinetics
2. 2003 High

   Functional expression of disease-associated missense mutations in MCC-deficient fibroblasts confirmed their pathogenicity by demonstrating null or severely reduced carboxylase activity, validating the causal link between specific MCCC1 residues and catalytic function.

   Evidence Transient transfection rescue in deficient fibroblasts with enzyme activity measurement and structural modelling against the E. coli biotin carboxylase crystal structure

   PMID:14680978

   Open questions at the time

   • Structural modelling relied on a bacterial homolog rather than the human MCC structure
   • Mechanism of substrate specificity for methylcrotonyl-CoA not addressed
3. 2012 High

   Crystal structure determination of the MCC holoenzyme revealed an unexpected architecture with previously unrecognized domains, providing the first atomic-level explanation for the catalytic mechanism and for how disease mutations disrupt function.

   Evidence X-ray crystallography of the MCC holoenzyme complex

   PMID:22869039

   Open questions at the time

   • Dynamics of biotin translocation between catalytic sites not captured by static structure
   • No co-crystal with the methylcrotonyl-CoA substrate reported
4. 2021 Medium

   Identification of lncRNA AABR07005593.1 as a physical binding partner of MCCC1 revealed an unexpected role for the enzyme in NF-κB pathway activation and inflammatory cytokine production, extending MCCC1 function beyond leucine catabolism.

   Evidence ChIRP-MS target identification with RNAi validation in rat alveolar macrophages and an in vivo PM2.5 inflammation model

   PMID:34619471

   Open questions at the time

   • Mechanism by which MCCC1–lncRNA interaction activates NF-κB is undefined
   • Single lab finding in a rat system without human cell validation
   • Unclear whether the catalytic activity of MCCC1 is required for this non-metabolic role
5. 2023 Medium

   Discovery that MCCC1 physically interacts with and stabilizes Bad in multiple myeloma cells established a non-canonical role for MCCC1 in mitochondrial apoptotic signaling and drug resistance.

   Evidence Co-immunoprecipitation, immunofluorescence, protein half-life assays, and xenograft models in multiple myeloma cells

   PMID:37805164

   Open questions at the time

   • Binding domain on MCCC1 responsible for Bad interaction not mapped
   • Whether this interaction occurs in non-cancer cells is untested
   • No reciprocal rescue experiment to confirm specificity
6. 2024 Medium

   Chemical probe-based target identification showed corosolic acid directly binds MCCC1, implicating the enzyme in insulin resistance signaling and suggesting it as a druggable target for glucose homeostasis.

   Evidence Avidin-biotin affinity pull-down with quantitative proteomics and in vitro binding confirmation; hypoglycemic effects in T2DM mice

   PMID:39731787

   Open questions at the time

   • Binding site of corosolic acid on MCCC1 not determined
   • Whether binding modulates carboxylase activity or a non-enzymatic function is unknown
   • Single lab; no genetic validation (e.g., MCCC1 KO rescue) provided
7. 2025 Medium

   lncBADR was shown to bind MCCC1 in T cells and inhibit BCAA degradation, causing intracellular BCAA accumulation that drives mTOR-Stat1-IFN-γ signaling and autoimmune pathology, connecting MCCC1's metabolic activity to adaptive immune regulation.

   Evidence T cell-specific lncBADR knockout mice with EAE model, RNA-protein binding assays, metabolic flux measurements, and dietary BCAA rescue

   PMID:41013574

   Open questions at the time

   • Binding interface between lncBADR and MCCC1 not characterized
   • Whether the effect is specific to MCCC1 or also mediated through concurrent Pcca binding is not resolved
8. 2025 Medium

   A PD-risk intronic variant (rs12637471) was shown to regulate MCCC1 expression in dopaminergic neurons using CRISPR-edited isogenic iPSCs, linking MCCC1 dysregulation to Parkinson's disease susceptibility.

   Evidence Postmortem brain mRNA analysis and CRISPR/Cas9 isogenic iPSC-derived dopaminergic neuron differentiation with expression quantification

   PMID:40216992

   Open questions at the time

   • Downstream functional consequences of elevated MCCC1 in neurons not characterized
   • No direct link to neurodegeneration phenotype beyond expression change
   • Single lab; needs replication and phenotypic readout (e.g., mitochondrial function, survival)

• How MCCC1's non-enzymatic interactions (with Bad, lncRNAs, and small molecules) relate to its canonical carboxylase activity, and whether catalytic and signaling roles are independent or coupled, remains unresolved.
• No mutagenesis studies separating catalytic from protein-interaction functions
• Structural basis of MCCC1 interaction with Bad and lncRNAs unknown
• Tissue-specific non-metabolic roles not systematically assessed